Latest Conference Articles

September 8th 2019, 7:54pm

IASLC World Conference on Lung Cancer

The investigational KRAS inhibitor AMG 510 induced near-universal disease control in patients with advanced non–small cell lung cancer with KRAS mutations.

July 28th 2019, 1:00am

International Lung Cancer Congress

Lyudmila A. Bazhenova, MD, medical oncologist, professor of clinical medicine, University of California, San Diego, discusses new developments in RET-rearranged non–small cell lung cancer.

July 28th 2019, 12:37am

International Lung Cancer Congress

Heather A. Wakelee, MD, professor of medicine (oncology), Stanford University Medical Center, discusses osimertinib and its role in treating patients with EGFR-mutant non–small cell lung cancer.

July 27th 2019, 11:14pm

International Lung Cancer Congress

With the arrival of immunotherapy to the small cell lung cancer armamentarium, combination approaches with targeted therapies are now in the pipeline to stimulate further clinical activity, such as adding PARP or CHK1 inhibitors.

July 27th 2019, 11:05pm

International Lung Cancer Congress

The magnitude of data becoming available on immunotherapy combinations for patients with non–small cell lung cancer has made treatment selection complicated.

July 27th 2019, 7:20pm

International Lung Cancer Congress

The early potential shown with the KRAS inhibitor AMG 510 coupled with several promising ongoing combination studies has ushered in the beginning of an exciting era for the treatment of KRAS-mutant non–small cell lung cancer.

July 27th 2019, 5:22am

International Lung Cancer Congress

Solange Peters, MD, PhD, of University Hospital Center Vaudois and Lausanne University in Switzerland, discusses the rapid advances in the lung cancer field and the importance of using biomarkers to create personalized immunotherapy treatments for patients.

July 27th 2019, 5:15am

International Lung Cancer Congress

Hossein Borghaei, DO, MS, chief of the Division of Thoracic Medical Oncology, professor of the Department of Hematology/Oncology, and co-director of the Immune Monitoring Facility at Fox Chase Cancer Center, discusses recent announcements from the CheckMate-227 trial in non–small cell lung cancer.

July 27th 2019, 4:59am

International Lung Cancer Congress

The frontline standard of care for patients with EGFR-mutant non–small cell lung cancer remains an EGFR TKI, most commonly osimertinib in the United States.

July 27th 2019, 4:38am

International Lung Cancer Congress

Checkpoint inhibitors in the neoadjuvant setting, as consolidation post-chemoradiation, or in combination with concurrent chemoradiation, are all strategies actively being pursued in the locally advanced non–small cell lung cancer setting.

July 26th 2019, 11:54pm

International Lung Cancer Congress

The future generation of agents in lung cancer should be evaluated in improved predictive biomarker-driven trials to identify patients who are most likely to benefit or have detriment for both TKIs and checkpoint inhibitors.

July 26th 2019, 5:46am

International Lung Cancer Congress

Roy S. Herbst, MD, PhD, chief of medical oncology, professor of medicine, Yale Cancer Center, Smilow Cancer Hospital, discusses combinations with immunotherapy in lung cancer.

July 26th 2019, 5:37am

International Lung Cancer Congress

Karen L. Reckamp, MD, MS, discusses pivotal findings with the highly selective MET inhibitors, tepotinib and capmatinib in patients with MET exon 14-altered advanced non–small cell lung cancer.

July 26th 2019, 4:20am

International Lung Cancer Congress

There is a growing need to share information across research settings and the community, with the rapid introduction of new biomarkers, cancer detection strategies, immunotherapies, and targeted therapies. This synchronization of system biology tool datasets could help create a new digital ecosystem focused on precision medicine.

July 26th 2019, 4:13am

International Lung Cancer Congress

Paul A. Bunn Jr, MD, highlights the benefits of preoperative window-of-opportunity studies, specifically with immunotherapy in lung cancer.

July 26th 2019, 2:09am

International Lung Cancer Congress

Optimizing the methods for preclinical research with an emphasis on patient-derived models, may help speed up the translation of new treatment advances from the laboratory to the clinic.

June 22nd 2019, 2:02am

International Conference on Malignant Lymphoma

Patients with high-risk relapsed/refractory chronic lymphocytic leukemia who failed or were intolerant of ibrutinib derived more benefit from CD19‐targeted CAR T-cell therapy when the BTK inhibitor was concurrently administered than when it was not.

June 21st 2019, 11:53pm

International Conference on Malignant Lymphoma

Tanya Siddiqi, MD, a hematologist/oncologist at City of Hope, discusses the phase I/II TRANSCEND CLL 004 trial, which evaluated the efficacy of anti-CD19 CAR T cells in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

June 21st 2019, 11:21pm

International Conference on Malignant Lymphoma

Nearly three-fourths of patients with relapsed/refractory primary mediastinal large B-cell lymphoma responded to a combination of nivolumab (Opdivo) plus brentuximab vedotin (Adcetris).

June 21st 2019, 10:41pm

International Conference on Malignant Lymphoma

The CAR T-cell therapy lisocabtagene maraleucel demonstrated high rates of response, including minimum residual disease in blood and marrow in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.